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Abstract 
Background: Elevated homocysteine (Hc) levels have a well‑established and clear causal relationship to epithelial 
damage leading to coronary artery disease. Furthermore, it is strongly associated with other metabolic syndrome vari‑
ables, such as hypertension, which is correlated with type II diabetes mellitus (T2DM). Studies on T2DM in relation to 
Hc levels have shown both positive and negative associations. The aim of the present study is to examine the relation‑
ship between Hc levels and risk of T2DM in the Lebanese population.
Methods: We sought to identify whether Hc associates positively or negatively with diabetes in a case–control study, 
where 2755 subjects enrolled from patients who had been catheterized for coronary artery diagnosis and treatment. 
We further sought to identify whether the gene variant MTHFR 667C>T is associated with T2DM, and how Hc and 
MTHFR 667C>T also impact other correlates of T2DM, including the widely used diuretics in this study population.
Results: We found that Hc levels were significantly reduced among subjects with diabetes compared to those with‑
out diabetes when adjusted for all potential confounders (OR 0.640; 95% CI [0.44–0.92]; p = 0.0200). The associations 
between Hc levels and other variates contradicted the result: hypertension associates positively with high Hc levels, 
and with T2DM. The MTHFR 667C>T only associated significantly with high Hc levels.
Conclusion: These results suggest population‑specific variations among a range of mechanisms that modulate the 
association of Hc and T2DM, providing a probe for future studies.
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Background
The prevalence of type II diabetes mellitus (T2DM) con-
tinues to increase worldwide [1, 2]. A recent study esti-
mated the prevalence of diabetes in the Middle East 
to be 9.3% [3], already more elevated than worldwide 
estimates of 8.3% in 2014 [4], with a rapid emergence 
due to recent dietary changes [5]. Given the significant 
healthcare-related expenditures, identifying modifiable 
factors is essential for the prevention of diabetes. T2DM 
is known to be a complex and heterogeneous disease 
resulting from a set of interacting factors that can be 
genetic or environmental, each with a variable contribu-
tion to disease causation. Many cultural, dietary, behav-
ioral, contextual and lifestyle factors are also primary 
determinants of risk for T2DM [6].
Recent studies have increasingly been showing inter-
actions between plasma Hc levels and T2DM and its 
vascular complications [7–9]. Correlation with T2DM 
remains unconvincing however, with studies report-
ing variability in plasma Hc levels between people with 
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a sulfur-containing, toxic non-proteinogenic amino-
acid biosynthesized from methionine. It is located at 
a branch-point of multiple metabolic pathways and is 
produced from methionine as a product of a number 
of transmethylation reactions [15]. The most common 
inherited disorder leading to hyperhomocysteinemia is 
the 5-methylenetetrahydrofolate reductase (MTHFR) 
polymorphism [16, 17]. Individuals with deficiencies of 
folic acid (B9), pyridoxine (B6), or cobalamin (B12) can as 
well develop hyperhomocysteinemia [18, 19].
To date, the mechanisms behind the T2DM correlation 
with Hc levels have been difficult to identify. MTHFR 
converts 5,10-methylenetetrahydrofolate to 5-methyl-
tetrahydrofolate. Mutations in MTHFR impair the func-
tion of the enzyme, and the 677C  →  T polymorphism 
(MTHFR, MIM # 607,093) is an enzyme reducing activ-
ity variant associated with elevated plasma Hc levels as 
well as insulin resistance. [20–22]. It is believed that the 
decreased insulin secretory responsiveness, caused by the 
destructive production of reactive oxygen species (ROS) 
as a result of elevated Hc levels, leads to insulin resist-
ance [23, 24]. It has also been suggested that in patients 
with insulin resistance, there is hepatic acceleration of 
glucocorticoid secretion that also leads to enhanced Hc 
catabolism and decreased plasma Hc levels [14].
Genetic modifiers of significant biological effect could 
promote our understanding of the mechanisms of action 
by which Hc levels and MTHFR variants contribute to 
T2DM. These mechanisms of interactions have not yet 
been comprehensively elucidated, and explanations of 
these interactions have been contradictory. The aim of 
the present study is to examine the relationship between 
Hc levels and risk of T2DM in a phenotypically well-
characterized group of patients and controls. We further 
investigate whether a dose–response relationship exists 
in our study population by assessing the interaction 
between the MTHFR 677C>T and Hc levels on T2DM. 
The Lebanese population may offer some unique features 
due to the rapid emergence of T2DM in Lebanon.
Methods
Subjects were recruited from several hospitals in Leba-
non between May 2007 and June 2013. We developed 
a questionnaire to measure the impact of T2DM risk 
factors and collected family history after obtaining an 
informed consent from participants, as approved by 
the Lebanese American University Institutional Review 
Board (IRB). Annotations were coded from medical 
charts for data such as laboratory tests, prescribed medi-
cations, and presence of other clinical conditions. Venous 
blood samples were drawn in ethylenediaminetetraacetic 
acid (EDTA) tubes from 7709 subjects. A diagnosis of 
T2DM was made when a patient had a hemoglobin A1C 
(HbA1C) value of 48 mmol/mol (6.5%) or higher and/or 
by an ascertained physician supported by documenta-
tion in the patient’s medical records. DNA was extracted 
using a standard phenol–chloroform extraction pro-
cedure. The single-nucleotide polymorphism (SNP) 
rs1801133 from MTHFR was determined for 1824 of the 
2755 study samples, having been analyzed using the Illu-
mina Human610 and 660 W Quad beadchip and the Illu-
mina Human Omni EXP-12v1 multi-use.
Plasma homocysteine level was determined for the 
2643 subjects by a microparticle enzyme immunoas-
say (MEIA) method (Abbott). The assay was carried 
out following the instructions of the manufacturer. 
Hyperhomocysteinemia was defined as a concentra-
tion of ≥15 μmol/l, and elevated Hc level as ≥10 μmol/l. 
1007 of these samples were genotyped. Dyslipidemia 
was defined as low high-density lipoprotein (HDL) (≤40 
for men, 50 for women), high triglycerides (≥200), and 
diagnosis of hyperlipidemia (DxHL). Since most sub-
jects had controlled low-density lipoprotein (LDL) with 
a protective effect against LDL levels ≥120 given a diag-
nosis of hyperlipidemia (OR 0.730, 95% CI = 0.60–0.89, 
p =  0.0014), elevated LDL levels were not included for 
analysis. Diagnoses of T2DM (DxT2DM) and hyperten-
sion (DxHTN) were also included. BMI in excess of 30 
(obesity) was also analyzed.
Besides summary statistics (Table  1), we sought to 
identify dominating covariates associated with hyper-
homocysteinemia. Noting T2DM negatively associ-
ated with hyperhomocysteinemia, we considered 
whether the structure of enrollment induced Berkson’s 
bias, and tested for interaction with enrollment cat-
egories. Prediction of T2DM by hyperhomocysteine-
mia was performed given adjustment variables, first by 
including only the adjustment variables, then including 
Table 1 Summary statistics, including counts of total par-
ticipants by  sex, coffee consumption, and  diabetes diag-
noses, and average (standard error of mean) for age, total 
cholesterol, HDL, LDL, Tg, Hc, and BMI levels
Total Male Female
Count 7709 5188 2517
Age 61.2 (11.4) 60.2 (11.6) 63.4 (10.8)
Total cholesterol 183.5 (46.8) 180.4 (46.2) 190.0 (47.7)
HDL 39.8 (12.1) 37.5 (10.6) 45.0 (13.4)
LDL 111.0 (41.9) 110.1 (41.9) 112.8 (41.9)
Tg 178.5 (113.0) 181.5 (116.1) 172.1 (105.9)
BMI 29.2 (5.3) 28.6 (4.8) 30.4 (6.0)
HTN 4722 2899 1821
Diabetes count 2404 1551 852
Homocysteine 14.9 (8.0) 15.6 (8.6) 13.4 (6.4)
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hyperhomocysteinemia and finally including interac-
tions between hyperhomocysteinemia with DxHTN. 
The adjustment variable analysis provides a baseline to 
identify shifts due to inclusion of hyperhomocysteine-
mia and its interaction with DxHTN. Following that, the 
same analysis of T2DM was repeated except that hyper-
homocysteinemia was replaced by elevated Hc levels. 
Finally, rs1801133 in MTHFR, known to promote hyper-
homocysteinemia, was tested for its effects on other 
metabolic syndrome variables and for elevated Hc and 
hyperhomocysteinemia.
Results
Table  1 shows summary statistics for metabolic syn-
drome, and Hc for the study population. It is notable that 
males make up most of the population and the average 
Hc levels were either borderline or fully hyperhomocyst-
eimic. Figure 1 shows the interaction between hyperten-
sion diagnosis and T2DM diagnosis on Hc levels in our 
study population. Hypertension diagnosis has a stronger 
impact on Hc levels among diabetics than among non-
diabetics. The difference in Hc levels between diabetics 
and non-diabetics is clearly greater than the difference 
in Hc levels between hypertensive and non-hypertensive 
subjects.
We tested for the presence of Berkson’s bias by exam-
ining whether the association between Hc levels and 
T2DM interacted with subjects’ enrollment. There was 
no significant association between enrollment and ele-
vated Hc levels (OR 0.870, 95% CI 0.72–1.05, p = 0.153), 
or hyperhomocysteinemia (OR 0.869, 95% CI 0.74–1.02, 
p =  0.0947). Table 2 shows very significant associations 
of hyperhomocysteinemia and elevated Hc with age and 
sex. Associations of hyperhomocysteinemia and elevated 
Hc with other variants were analyzed with and without 
adjustment with sex and age. T2DM is suppressed among 
subjects with elevated Hc with and without adjustment, 
but not among subjects with hyperhomocysteinemia. 
Hypertension is significantly promoted both by hyperho-
mocysteinemia and elevated Hc.
Table  3A shows the impact of hyperhomocysteine-
mia on T2DM considering adjustments from the other 
covariates. Inclusion of the strongest covariates (age, 
sex included as adjustment variables but not reported), 
DxHL, obesity, and DxHTN were all highly significant. 
Inclusion of hyperhomocysteinemia tended to shift the 
other adjustment variable odds ratios marginally, with 
BMI losing high significance, yet remaining significant; 
hyperhomocysteinemia was significant. Inclusion of the 
interaction with hypertension was not significant, but 
hyperhomocysteinemia remained significant. Table  3B 
shows patterns similar to that of 3A except that elevated 
Hc levels had more pronounced OR values and were 
more highly significant.
Table 4 summarizes the allele frequencies of rs1801133 
in the study population, with Hardy–Weinberg disequi-
librium almost significant. Table 5 repeats Table 2, except 
that Hc levels are replaced by rs1801133 in an additive 
logistic regression. All associations were not statistically 
significant except for those involving Hc. Hyperhomo-
cysteinemia was highly significant (OR  1.483, 95% CI 
1.20–1.83, p  =  0.000237), with elevated Hc being only 
significant (OR 1.287, 95% CI 1.05–1.59, p = 0.0173).
Discussion
To our knowledge, this is the first study done on the 
Lebanese population to examine the correlation of 
homocysteine levels and T2DM. The mean Hc plasma 
levels in patients without diabetes in our study popula-
tion (15.3  ±  8.7) was elevated and found to be higher 
than what has been reported in previous studies 
(range = 12–14 mmol/l) [25]. We observed a significantly 
negative correlation between hyperhomocysteinemia and 
T2DM. This negative correlation remained significant 
whether Hc plasma levels where ≥10 or ≥15, indicating 
a consistent threshold association. Given the correlation 
of T2DM and coronary artery disease (CAD), a previous 
study conducted on our study subjects showed an associ-
ation of hyperhomocysteinemia with the degree of coro-
nary artery stenosis in CAD patients [26].
Our results are not aligned with the overwhelming 
majority of previous studies that have reported a posi-
tive correlation between elevated Hc and T2DM and its 
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Fig. 1 Homocysteine (Hc) levels showing interaction between 
hypertensive (DxHTN 1) and non‑hypertensive (DxHTN 0) diabetic 
(DxT2DM True) and non‑diabetic (DxT2DM False) subjects
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Table 2 Predicting clinical metabolic syndrome variates from  homocysteine, both  unadjusted, and  adjusted with  sex 
and age


























































































Table 3 Predicting T2DM, adjusted by sex = male and age ≥ 60
Each block reports OR, (95%CI), and p-value
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conducted on more than 8000 subjects provided strong 
support for a causal association of elevated Hc levels and 
T2DM [30]. This meta-analysis study, however, used pub-
lished data from various studies that may have had differ-
ent patient recruitment criteria and clinical definitions 
with many including small number of subjects. Measure-
ments of Hc levels were not homogenous across all popu-
lations with each having a distinct genetic background 
hence leading to significant heterogeneity. This data vari-
ability may explain some of the difference in their findings 
compared to ours. One study in particular, conducted on 
105 subjects with diabetes and 120 controls matched for 
sex showed that the mean fasting Hc was significantly 
lower in patients with diabetes than control subjects 
[13]. A study conducted on Mediterranean patients with 
T2DM did not show a difference in Hc levels between dia-
betic and non-diabetic patients [31], while a study done by 
Russo et al. [32] did not show a difference between total 
Hc among diabetic and non-diabetic women, suggesting 
a possible gender effect on this association. Moreover, 
despite the strong evidence showing the causal association 
of Hcy level with the development of T2DM [30], the Pro-
spective Investigation of the Vasculature study in Uppsala 
Seniors (PIVUS) cohort (n  =   1016) showed no evidence 
of a causal relationship of levels of plasma homocysteine 
with fasting glucose, fasting insulin, or T2DM [33].
The reduction of Hc levels among subjects with diabe-
tes could possibly be attributed to two factors. First, Hc is 
located at a branch-point of multiple metabolic pathways 
and is produced from methionine as a product of a large 
number of transmethylation reactions [15]. Homocysteine 
methyltransferase (MTHFR) and cystathionine beta syn-
thase (CBS) carry out a chemical reaction that converts 
Hc to methionine when Hc is methylated by N-5-methyl-
tetrahydrofolate. This remethylation reaction is the main 
regulator of plasma Hc levels. Second, it was consist-
ently shown that in rats with diabetes, the expression of 
CBS is significantly increased. Hc levels were significantly 
increased when these rats with diabetes received insulin. 
These results strongly suggest a regulatory role of insulin 
in the hepatic trans-sulfuration pathway that metabolizes 
Hc. In  vitro studies conducted on cultured hepatocytes 
also demonstrated an increased activity of CBS [34].
It has been postulated that as modulators of Hc, 
MTHFR variants that inactivate MTHFR or lower its 
activity may be directly associated with increased risk of 
T2DM. Although previous studies have shown an asso-
ciation between MTHFR 677C>T and complications of 
diabetes like retinopathy [35, 36] and nephropathy [37], 
none could recognize this activity lowering variant as a 
risk factor for T2DM, and therefore the negative asso-
ciation that we observe remains questionable. Moreover, 
mild hyperhomocysteinemia and the MTHFR TT geno-
type were not shown to be significant risk factors for the 
development of microangiopathy in patients with T2DM 
in one prospective cohort study by Russo et al. [38]. This 
suggests that there are other confounding variables not 
yet identified that may be impacting Hc levels and T2DM, 
which are not related to MTHFR mutations. In a recent 
meta-analysis study, a link between MTHFR 677C>T and 
T2DM was established, showing that subjects with the T 
Table 4 MTHFR667 (rs1801133) genotype and  allele fre-
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allele of the MTHFR 677C>T variant have significantly 
higher risk of having diabetes (OR 1.31, p = 0.032) than 
carriers of the C allele [30].
In our study we failed to show a direct association 
between the MTHFR 677C>T variant and T2DM. This 
suggests that there are other causes to hyperhomocyst-
einemia acting in our population that impact its asso-
ciation either directly or through high Hc levels with 
hypertension not accounted for by MTHFR 677C>T. 
We did not resolve an interaction between diuretics and 
MTHFR 677C>T in predicting hyperhomocysteinemia, 
but additive regression showed both contributed highly 
significant OR’s. Yet, MTHFR 677C>T shows no signifi-
cant association with T2DM. One possible reason behind 
the difference observed from the various studies associat-
ing MTHFR with T2DM is the genetic heterogeneity of 
the various populations studied. The frequencies of the 
MTHFR 677 alleles vary significantly from one popula-
tion to another. The T allele ranges from 8.8% in Moroc-
cans [39] to 19.1% in Chinese [40] population while it 
was 34.3% in our study, which although yields increased 
power, but limitations in the number genotyped restrict 
power. A systematic review by Zhong et al. [41] showed 
that rs1801133 polymorphism of the MTHFR gene was 
not consistently associated with either increased or 
reduced risk of T2DM.
Limitations
All enrolled subjects were catheterized. Catheteriza-
tion was performed for myocardial infarction, unstable 
angina, and subjects warranting workup due to high CAD 
risk factors. We therefore tested whether the negative 
association between hyperhomocysteinemia and T2DM 
might be due to Berkson’s bias, and found that there 
was no association between reason for catheterization 
and the relationship between homocysteine levels with 
T2DM. Another limitation of the study is the absence of 
data related to levels of vitamins B9 (folate) and B12 or 
creatinine levels reflecting kidney functions; thus these 
parameters were not included in the final multivariate 
analysis despite being associated with homocysteinemia.
Conclusion
We speculate that the role of MTHFR and their interac-
tion with insulin and glucose levels in the blood shows 
mixed pressures on both positive and negative associa-
tions between Hc levels and T2DM, and the conditions 
reflected in populations producing these disparate results 
need to be further elucidated. The expression regula-
tion of these enzymes is a complex process that may 
involve the activity of other enzymes as well as the cel-
lular environment that is affected by diet, cellular stress 
and genomic background and the epigenetic milieu. The 
interaction between glucose metabolism, insulin resist-
ance and the pathogenicity of hyperhomocysteinemia 
remains to be unraveled.
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